Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers

Mimma Rizzo,1 Patrizia Giannatempo,2 Camillo Porta1,3 1Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy; 2Department of Medical Oncology, Fondazione I.R.C.C.S. Istituto Nazionale dei Tumori, Milan, Italy; 3Department of Biomedical Sciences and Human Oncology, Univers...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rizzo M, Giannatempo P, Porta C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	metastatic urothelial carcinoma targeted therapy immune checkpoint inhibitors first-line treatment second-line treatment Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/77823714dbc345eea82281987cebfa04
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:77823714dbc345eea82281987cebfa04
record_format	dspace
spelling	oai:doaj.org-article:77823714dbc345eea82281987cebfa042021-12-02T17:25:13ZBiological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers1177-5491https://doaj.org/article/77823714dbc345eea82281987cebfa042021-11-01T00:00:00Zhttps://www.dovepress.com/biological-therapeutic-advances-for-the-treatment-of-advanced-urotheli-peer-reviewed-fulltext-article-BTThttps://doaj.org/toc/1177-5491Mimma Rizzo,1 Patrizia Giannatempo,2 Camillo Porta1,3 1Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy; 2Department of Medical Oncology, Fondazione I.R.C.C.S. Istituto Nazionale dei Tumori, Milan, Italy; 3Department of Biomedical Sciences and Human Oncology, University of Bari ‘A. Moro’, Bari, ItalyCorrespondence: Camillo PortaDepartment of Biomedical Sciences and Human Oncology, University of Bari “A. Moro”, Piazza Giulio Cesare, 11, Bari, 70124, ItalyTel +39-080-5594167Email camillo.porta@gmail.comAbstract: In recent years, diagnostic and therapeutic advances have contributed to a reduction in mortality rates of patients with metastatic urothelial carcinoma (mUC). Immune checkpoint inhibitors have demonstrated efficacy and safety as both first-line and first-line switch maintenance therapy for mUC. For platinum-refractory patients, in addition to immunotherapy, other targeted agents (antibody–drug conjugates and fibroblast growth factor receptor inhibitors) have been approved after demonstrating a clinically relevant advantage in overall response rate, progression-free survival, and overall survival compared to standard of care. Sequential treatment strategies are finally feasible for patients with advanced urothelial carcinoma. This review will summarize the results of the most important phase II–III clinical trials for first-line, switch maintenance, second-line, and subsequent lines of therapy, and describe the most promising clinical trials currently ongoing in these treatment scenarios.Keywords: metastatic urothelial carcinoma, targeted therapy, immune checkpoint inhibitors, first-line treatment, second-line treatmentRizzo MGiannatempo PPorta CDove Medical Pressarticlemetastatic urothelial carcinomatargeted therapyimmune checkpoint inhibitorsfirst-line treatmentsecond-line treatmentMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 15, Pp 441-450 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	metastatic urothelial carcinoma targeted therapy immune checkpoint inhibitors first-line treatment second-line treatment Medicine (General) R5-920
spellingShingle	metastatic urothelial carcinoma targeted therapy immune checkpoint inhibitors first-line treatment second-line treatment Medicine (General) R5-920 Rizzo M Giannatempo P Porta C Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
description	Mimma Rizzo,1 Patrizia Giannatempo,2 Camillo Porta1,3 1Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Bari, Italy; 2Department of Medical Oncology, Fondazione I.R.C.C.S. Istituto Nazionale dei Tumori, Milan, Italy; 3Department of Biomedical Sciences and Human Oncology, University of Bari ‘A. Moro’, Bari, ItalyCorrespondence: Camillo PortaDepartment of Biomedical Sciences and Human Oncology, University of Bari “A. Moro”, Piazza Giulio Cesare, 11, Bari, 70124, ItalyTel +39-080-5594167Email camillo.porta@gmail.comAbstract: In recent years, diagnostic and therapeutic advances have contributed to a reduction in mortality rates of patients with metastatic urothelial carcinoma (mUC). Immune checkpoint inhibitors have demonstrated efficacy and safety as both first-line and first-line switch maintenance therapy for mUC. For platinum-refractory patients, in addition to immunotherapy, other targeted agents (antibody–drug conjugates and fibroblast growth factor receptor inhibitors) have been approved after demonstrating a clinically relevant advantage in overall response rate, progression-free survival, and overall survival compared to standard of care. Sequential treatment strategies are finally feasible for patients with advanced urothelial carcinoma. This review will summarize the results of the most important phase II–III clinical trials for first-line, switch maintenance, second-line, and subsequent lines of therapy, and describe the most promising clinical trials currently ongoing in these treatment scenarios.Keywords: metastatic urothelial carcinoma, targeted therapy, immune checkpoint inhibitors, first-line treatment, second-line treatment
format	article
author	Rizzo M Giannatempo P Porta C
author_facet	Rizzo M Giannatempo P Porta C
author_sort	Rizzo M
title	Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
title_short	Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
title_full	Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
title_fullStr	Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
title_full_unstemmed	Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
title_sort	biological therapeutic advances for the treatment of advanced urothelial cancers
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/77823714dbc345eea82281987cebfa04
work_keys_str_mv	AT rizzom biologicaltherapeuticadvancesforthetreatmentofadvancedurothelialcancers AT giannatempop biologicaltherapeuticadvancesforthetreatmentofadvancedurothelialcancers AT portac biologicaltherapeuticadvancesforthetreatmentofadvancedurothelialcancers
_version_	1718380917984067584

Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers

Ejemplares similares